Sarepta Therapeutics Files 8-K: Director Changes & Compensation Updates
Ticker: SRPT · Form: 8-K · Filed: Dec 8, 2025 · CIK: 873303
Sentiment: neutral
Topics: corporate-governance, executive-compensation, board-changes
Related Tickers: SRPT
TL;DR
Sarepta's board is changing, exec pay is being updated. Check the 8-K.
AI Summary
On December 7, 2025, Sarepta Therapeutics, Inc. filed an 8-K report detailing the departure of a director, the election of new directors, and updates to executive compensation arrangements. The filing also includes financial statements and exhibits.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in board and executive compensation can sometimes precede or reflect significant strategic shifts or internal challenges.
Key Players & Entities
- Sarepta Therapeutics, Inc. (company) — Registrant
- Delaware (jurisdiction) — State of Incorporation
- 001-14895 (company_id) — Commission File Number
- 93-0797222 (company_id) — IRS Employer Identification Number
FAQ
Who has departed from Sarepta Therapeutics' board of directors?
The filing indicates the departure of a director, but the specific name is not provided in the initial summary of the 8-K.
When was the earliest event reported in this 8-K filing?
The earliest event reported is dated December 7, 2025.
What are the main items covered in this 8-K filing?
The filing covers the departure of directors, election of directors, appointment of officers, and compensatory arrangements of certain officers, along with financial statements and exhibits.
What is Sarepta Therapeutics' SIC code?
Sarepta Therapeutics' Standard Industrial Classification (SIC) code is 2834, for Pharmaceutical Preparations.
Where is Sarepta Therapeutics headquartered?
Sarepta Therapeutics' business address is 215 First Street, Suite 415, Cambridge, MA 02142.
Filing Stats: 768 words · 3 min read · ~3 pages · Grade level 12.1 · Accepted 2025-12-08 07:33:39
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share SRPT Nasdaq Glo
- $6 m — grant date fair value of approximately $6 million, that vest annually over the thre
- $6 million — grant date fair value of approximately $6 million measured at target, is eligible to be e
Filing Documents
- d15497d8k.htm (8-K) — 27KB
- d15497dex101.htm (EX-10.1) — 87KB
- 0001193125-25-310588.txt ( ) — 241KB
- srpt-20251207.xsd (EX-101.SCH) — 3KB
- srpt-20251207_lab.xml (EX-101.LAB) — 17KB
- srpt-20251207_pre.xml (EX-101.PRE) — 11KB
- d15497d8k_htm.xml (XML) — 3KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 10.1+ Omnibus Equity Award Agreement, dated as of December 7, 2025, between the Company and Douglas S. Ingram 104 The cover page from this Current Report on Form 8-K of Sarepta Therapeutics, Inc., formatted in Inline XBRL and included as Exhibit 101 + Portions of this exhibit (indicated by asterisks) have been redacted pursuant to Item 601 of Regulation S-K because they are both not material and the registrant customarily and actually treats such information as private and confidential.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Sarepta Therapeutics, Inc. Date: December 8, 2025 By: /s/ Cristin L. Rothfuss Cristin L. Rothfuss Executive Vice President, Chief General Counsel